Company: RGNT
Filing Date: 2025-10-24
Form Type: F-1/A
Source: 0001213900-25-101900
Chunk: 119

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-10-24
Form: F-1/A
Chunk 119
---
 denatured fibrinogen controlled erosion 
 for the regeneration of hyaline-like cartilage;                                                                                     |

| ● | Initial state as liquid                                                                                                          
 form provides for complete and optimal defect filling and subsequent curing hardens it into a more solid body, and holding it in 
 place;                                                                                                                           |

| ● | Single, 10 minutes surgical 
 procedure;                  |

| ● | Implantable via open or                 
 minimally-invasive surgical techniques; |

| ● | Manufacturing process allows               
 for low cost of goods and scalability; and |

| ● | Intended for the repair                                     
 of focal defects in cartilage and/or osteochondral defects. |

All of these advantages were
demonstrated in the Pilot Study where the recovery of the patient took approximately two weeks of non-weight bearing activity, and led
to a full recovery within three to six months. Additionally, 100% of the participants who were followed up with in the Pilot study reported
no pain in their recovery through at least four years thereafter.

Future Products; Additional Applications

Based on similarity of mechanism
of action for cartilage and based on animal studies performed by the Company for osteoarthritis, we believe that in the future, our Gelrin
technology platform may also provide a solution to osteoarthritis and other cartilage injuries related to the ankle, wrist, and elbow.

| ● | GelrinP – a paste                                                                                                                      
 form of GelrinC, which is cured with UV light, developed for treatment of injuries in smaller joints like the ankle, wrist, and elbow. |

| ● | GelrinV – Novel intra-articular                                                                                                  
 injectable gel, long-lasting with pro-healing capabilities. It is a thermo-responsive, hydrophobic polymer, which is injected as 
 a thin liquid, and turns into a thick gel at body temperature. Targeted for treatment of moderate osteoarthritis.                |

Clinical Development of GelrinC

Completed Pilot Study

In medical devices, the efficacy
trial first tested on larger groups of patients is called a pilot study. We carried out the Pilot Study on 56 patients that were treated
with GelrinC and followed up for up to four years in multiple sites in Northern Europe and Israel. The primary efficacy endpoints were
changes from baseline for overall KOOS scores and KOOS pain subscale at 18 months and the primary efficacy end points were met. No serious
adverse events were observed in the completed Pilot Study. In addition to pre-clin